Featured Content

Dean Gesme, MD
FACP FACPE FASCO President, Minnesota Oncology

Sen. Ted Cruz Wants To Change The Way The FDA Approves Drugs

(Forbes) Feb 3, 2016 - Giving Congress the right to overrule FDA approval decisions would make the process more political than scientific.

Commentary: All I can say is "Political Hubris" beyond measure!



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia

(Amgen) Feb 4, 2016 - Amgen today announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study.
read corporate press release »

NIH Researchers Identify Striking Genomic Signature Shared By Five Types Of Cancer

(NIH) Feb 5, 2015 - National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer. They also found evidence that this methylation signature may be present in many more types of cancer.
read press release »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Sen. Ted Cruz Wants To Change The Way The FDA Approves Drugs (Forbes)

All I can say is "Political Hubris" beyond measure!posted by: Dean Gesme, MD

TV Ads for Lung Cancer Drug Are Needed, Says BMS (Medscape Medical News)

At the risk of offending my friends in the pharmaceutical industry, I strongly feel that DTC advertising is bad....posted by: Thomas Marsland, MD

Costs of Targeted Anticancer Drugs Growing Faster Than Usage (Philadelphia Inquirer)

As long as the targets are present and appropriate, targeted therapy is only bad from an episodic cost standpoint,...posted by: Winston Wong, PharmD

Even Talking About Reducing Drug Prices Can Reduce Drug Prices (New York Times/The Upshot)

So even during the campaign rhetoric of lower drug prices, most major manufacturers took their annual price increases...posted by: Winston Wong, PharmD

Calls Intensify To Get Medicare To Pay For Genetic Sequencing Of Tumors (STAT)

So this article stimulated a response that could be also used to reply to several of the reports in today's OBR....posted by: Thomas Marsland, MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Ipsos has 2 jobs posted.


Seattle Genetics has 1 job posted.


Bayer Pharmaceuticals has 1 job posted.


Touchpoint Solutions has 1 job posted.


Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
IMMU +20.88%
SCLN +8.01%
VBLT +7.28%
KITE -12.12%
OHRP -10.48%
PBYI -9.69%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: February 2016
Company: Heron Therapeutics
Product: SUSTOL® (granisetron) Injection

Date: Q1 2016
Company: Celldex Therapeutics, Inc.
Product: Rintega® (rindopepimut)

Date: Q1 2016
Company: Celator Pharmaceuticals
Product: CPX-351 (cytarabine:daunorubicin) Liposome for Injection

See All OBR Radar items»